Not yet recruiting
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
NCT07748624
- Conditions
- Arthralgia, Arthritis, Joint Diseases, +7 more
- Locations
-
Not specified